Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CUBIST PHARMACEUTICALS (CBST) -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (230)	10/17/2008 7:35:34 AM
From: idos	Respond to of 252

UPDATE 1-Cubist posts higher Q3 profit on Cubicin sales reuters.com Q3 profit rises 38 pct Revenue up 41 pct *Cubicin sales up 45 pct (Recasts; adds details) Oct 16 (Reuters) - Cubist Pharmaceuticals Inc (CBST) posted a 38 percent rise in quarterly profit, helped by strong sales of Cubicin, its antibiotic injection to treat bacterial infections. Net income for the third quarter was $27.9 million, or 44 cents per share, compared with $20 million, or 32 cents per share, a year earlier. Excluding stock-based compensation expenses, Cubist earned 48 cents a share. Total revenue rose 41 percent to $112.4 million. Cubicin sales rose 45 percent. Analysts were expecting the company to earn 33 cents a share, excluding special items but including stock-based compensation expenses, on revenue of $108.7 million, according to Reuters Estimates.